Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19
Review
[키워드] benefit-risk profile
biological activity
caused
circulation
clinical
Clinical deterioration
clinical trials
condition
Coronavirus disease 2019
COVID-19
cytokine
Cytokines
effective
Efficacy
feasibility
Increased
Inflammatory bowel disease
inflammatory disease
inhibitor
International standards
Intervention
Mortality
Necrosis
outcome
pathogenesis of COVID-19
patients with COVID-19
preventing disease
pro-inflammatory cytokine
progression
randomised
reduction in
repurposing
rheumatoid arthritis
SARS-CoV-2
therapeutic agent
therapy
TNF
Trial
Tumour necrosis factor (TNF)
Tumour necrosis factor (TNF).
Vaccine
Vaccines
ventilator
[DOI] 10.1016/j.biopha.2021.111785 PMC 바로가기 [Article Type] Review
[DOI] 10.1016/j.biopha.2021.111785 PMC 바로가기 [Article Type] Review